Lyra Therapeutics (NASDAQ:LYRA – Get Free Report) issued its quarterly earnings data on Tuesday. The company reported ($0.12) EPS for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.03, Zacks reports. The firm had revenue of $0.18 million during the quarter, compared to the consensus estimate of $0.16 million. Lyra Therapeutics had a negative return on equity of 125.07% and a negative net margin of 6,635.76%.
Lyra Therapeutics Price Performance
LYRA opened at $0.11 on Thursday. The stock’s 50 day moving average price is $0.13 and its 200 day moving average price is $0.18. The stock has a market cap of $6.92 million, a P/E ratio of -0.07 and a beta of 0.04. Lyra Therapeutics has a 12 month low of $0.08 and a 12 month high of $0.42.
Analyst Ratings Changes
Separately, HC Wainwright reiterated a “neutral” rating and issued a $2.00 price objective on shares of Lyra Therapeutics in a research report on Friday, March 14th.
About Lyra Therapeutics
Lyra Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration.
Featured Stories
- Five stocks we like better than Lyra Therapeutics
- What Does a Stock Split Mean?
- Upwork’s Earnings Beat Fuels Stock Rally—Is Freelancing Booming?
- Basic Materials Stocks Investing
- Tempus AI Stock: Time to Double Down or Cut and Run?
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- DexCom Stock: Earnings Beat and New Market Access Drive Bull Case
Receive News & Ratings for Lyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
